SCHEMBL22098005

SCHEMBL22098005

COC(=O)c1ccc(-c2nc(Nc3cnn(C(=O)OC(C)(C)C)c3)ncc2F)cc1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK2 Q92630 6/20 0.46
MAPK8 P45983 2/20 0.42
GSK3B P49841 2/20 0.42
CAMKK2 Q96RR4 2/20 0.42
PIK3CG P48736 1/20 0.42
SCD O00767 1/20 0.40
CCNE2 O96020 3/20 0.39
CCNE1 P24864 3/20 0.39
CDK2 P24941 3/20 0.39
CDK6 Q00534 1/20 0.38
EGFR P00533 1/20 0.38
ITK Q08881 1/20 0.38
MAPK1 P28482 1/20 0.38
JAK2 O60674 1/20 0.38
JAK1 P23458 1/20 0.38
TYK2 P29597 1/20 0.38
JAK3 P52333 1/20 0.38
KCNH2 Q12809 2/20 0.38
CCNB2 O95067 3/20 0.38
CDK1 P06493 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22097953 0.84 CCNE2 (0.51) MAPK8GSK3BCAMKK2PIK3CGCCNE2
SCHEMBL30956511 0.84 DYRK2 (0.46) DYRK2MAPK8GSK3BCAMKK2PIK3CG
SCHEMBL28617786 0.84 DYRK2 (0.46) DYRK2MAPK8GSK3BCAMKK2PIK3CG
SCHEMBL24853544 0.80 CDK4 (0.52) CDK2CDK6JAK2JAK1TYK2
SCHEMBL27059155 0.80 MAPK8 (0.45) MAPK8GSK3BCAMKK2PIK3CGCDK2
SCHEMBL24852496 0.78 DYRK2 (0.43) DYRK2SCDCCNE1CDK2JAK2
SCHEMBL16690760 0.78 MAPK1 (0.49) MAPK1
SCHEMBL24853225 0.77 JAK1 (0.50) GSK3BCCNE2CCNE1CDK2MAPK1
SCHEMBL24852463 0.77 MAPK8 (0.46) MAPK8GSK3BCAMKK2PIK3CGCDK2
SCHEMBL27447231 0.75 JAK3 (0.51) JAK2JAK1TYK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12098142-B2 Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-09-24 US disclosed
US-12030870-B2 Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-07-09 US disclosed
US-12030870-B2 Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-07-09 US disclosed
US-20240083881-A1 BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-03-14 US disclosed
US-20240025882-A1 BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-01-25 US disclosed
US-20240025882-A1 BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-01-25 US disclosed
US-20230002362-A1 BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-01-05 US disclosed
WO-2020119819-A1 BENZAMIDES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2020-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240083881-A1 BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF JAK1, JAK3, JAK2 DYRK2 600/4885MAPK8 593/4885GSK3B 567/4885
US-12030870-B2 Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof JAK2, JAK1, JAK3 DYRK2 1112/4885MAPK8 728/4885GSK3B 1177/4885
US-12098142-B2 Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof JAK1, JAK3, JAK2 DYRK2 908/4885MAPK8 680/4885GSK3B 1107/4885
US-20230002362-A1 BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF JAK1, JAK3, JAK2 DYRK2 600/4885MAPK8 593/4885GSK3B 567/4885
US-20240025882-A1 BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF JAK2, JAK1, JAK3 DYRK2 1112/4885MAPK8 728/4885GSK3B 1177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.